Core Points - On November 12, Century Huatong announced a share repurchase plan of 500 million to 1 billion yuan for capital reduction [1][2] - A total of 18 A-share listed companies disclosed share reduction plans, indicating a trend of shareholder divestment [1][2] Summary of Share Repurchase - Century Huatong plans to repurchase shares worth between 500 million and 1 billion yuan to reduce registered capital [2] Summary of Share Reductions - Tai Xiang Co. plans to reduce no more than 1% of its shares by shareholder Zhongyuan Investment [2] - Jiang Bolong's second-largest shareholder has completed a reduction of 4.1915 million shares [2] - Senior management of Zhejiang Zhongcheng plans to reduce their holdings [2] - Controlling shareholder of Hexing Packaging intends to reduce no more than 1.91% of shares [2] - Shareholder Wang Ge of Dongfang Zhongke plans to reduce no more than 0.51% of shares [2] - Executive Yu Qingchi of Kuai Publishing plans to reduce no more than 0.02% of shares [2] - Directors and executives of Changlian Co. plan to collectively reduce no more than 0.77% of shares [2] - China Unicom's structural adjustment fund reduced 40.7003 million shares from November 10 to November 12 [2] - Shareholder Chen Bei of Ruimaite plans to reduce no more than 1.76% of shares [2] - Shareholder Zhang Hong of Aipeng Medical plans to reduce no more than 2% of shares [2] - Director Wo Jinye of Jujiao Co. plans to reduce no more than 0.01% of shares [2] - Directors and executives of Zhonglan Environmental Protection plan to reduce their holdings [2] - Shareholders Ning Kangqi and Beikangqi of Hendi Pharmaceutical plan to collectively reduce no more than 2.33% of shares [2] - Wuxi High-tech Zone New Momentum Industry Development Fund reduced 549,200 shares of Xiangnan Chip [2] - Controlling shareholder of Tianji Co. sold 8.4 million shares during a period of significant stock trading volatility [2] - The second-largest shareholder of Fangzheng Electric reduced a total of 1.6324 million shares on November 10 and 12 [2] - Controlling shareholder of Haodangjia plans to reduce no more than 2.7% of shares [2] - Controlling shareholder of Zhibang Home reduced 905,000 convertible bonds [2]

Group 1 - The core point of the article is that Hendi Pharmaceutical reported a total of 22,155 shareholders as of November 10, 2025 [2]

Summary of Key Points Core Viewpoint - The article discusses various companies and their shareholders' intentions to buy or sell shares, indicating a trend of both increasing and decreasing shareholdings among different firms in the market [1]. Company Actions - 康缘药业's actual controller's concerted action party increased holdings by 80,000 shares [1]. - 好当家's controlling shareholder plans to reduce holdings by no more than 2.7% [1]. - 亨迪药业's shareholders, including 宁康企管, 倍康企管, and 雷小艳, intend to collectively reduce holdings by no more than 2.33% [1]. - 合兴包装's controlling shareholder 新疆兴汇聚 plans to reduce holdings by no more than 1.91% [1]. - 瑞迈特's shareholder 陈蓓 intends to reduce holdings by no more than 1.76% [1]. - 泰祥股份's 众远投资 plans to reduce holdings by no more than 1% [1]. - 香农芯创's 无锡高新区新动能产业发展基金 reduced holdings by 549,200 shares [1]. - 中国联通's structural adjustment fund will reduce holdings by 40,700,300 shares from November 10 to November 12 [1]. - 方正电机's shareholder 张敏 reduced holdings by 1,632,400 shares [1]. - 畅联股份's directors 徐峰 and 陈文晔 plan to reduce holdings by 0.57% and 0.20%, respectively [1]. - 中兰环保's shareholders 王广庆, 曹丽, and 李泉 plan to reduce holdings by 0.0375%, 0.2798%, and 0.0275%, respectively [1]. - 聚胶股份's director 沃金业 plans to reduce holdings by 0.01% [1]. - 浙江众成's executives 黄旭生 and 潘德祥 plan to reduce holdings by 0.0140% [1]. - 东方中科's shareholder 王戈 plans to reduce holdings by 0.51% [1]. - 海南瑞泽's vice president 于清池 plans to reduce holdings by no more than 0.02% [1].

公告显示，宁康企管本次计划合计减持数量不超过417.6万股，不超过公司总股本的1%；倍康企管本次 计划合计减持数量不超过139.2万股，不超过公司总股本的0.33%；雷小艳本次计划合计减持数量不超过 417.6万股，不超过公司总股本的1%。 北京商报讯（记者 丁宁）11月12日晚间，亨迪药业（301211）发布公告称，公司于近日收到宁康企 管、倍康企管、雷小艳出具的《关于股份减持计划的告知函》。 ...

Core Viewpoint - Hendi Pharmaceutical (301211.SZ) announced plans for significant share reductions by major shareholders, indicating potential changes in ownership structure and market sentiment towards the company [1] Group 1: Shareholder Reductions - Jingmen Ningkang Enterprise Management Center (Limited Partnership), holding 23,490,000 shares (5.63% of total shares), plans to reduce its holdings by up to 4,176,000 shares (1% of total shares) within three months after the announcement [1] - Jingmen Beikang Enterprise Management Center (Limited Partnership), holding 7,830,000 shares (1.88% of total shares), intends to reduce its holdings by up to 1,392,000 shares (0.33% of total shares) within three months after the announcement [1] - Lei Xiaoyan, holding 15,660,000 shares (3.75% of total shares), plans to reduce her holdings by up to 4,176,000 shares (1% of total shares) within three months after three trading days from the announcement [1]

Summary of Key Points Core Viewpoint - Hendi Pharmaceutical (301211.SZ) announced plans for significant share reductions by major shareholders, indicating potential changes in ownership structure and market sentiment towards the company [1] Group 1: Shareholder Reductions - Shareholder Ningkang Enterprise Management Center (Limited Partnership) plans to reduce its holdings by up to 4,176,000 shares, representing 1% of the total share capital, within three months after the announcement [1] - Shareholder Beikang Enterprise Management Center (Limited Partnership) intends to reduce its holdings by up to 1,392,000 shares, accounting for 0.33% of the total share capital, within the same timeframe [1] - Shareholder Lei Xiaoyan plans to reduce her holdings by up to 4,176,000 shares, also representing 1% of the total share capital, within three months after three trading days from the announcement [1]

Core Viewpoint - Hendi Pharmaceutical Co., Ltd. announced a share reduction plan involving three shareholders, aiming to reduce a total of up to 9.744 million shares, representing 2.33% of the company's total share capital [1][2]. Share Reduction Plan Details - The share reduction plan involves three shareholders: Jingmen Ningkang Enterprise Management Center (Limited Partnership), Jingmen Beikang Enterprise Management Center (Limited Partnership), and Lei Xiaoyan, all citing "personal financial planning" as the reason for the reduction [2]. - The specific reduction plans are as follows: - Ningkang Enterprise plans to reduce up to 4.176 million shares (1% of total shares) from December 4, 2025, to March 3, 2026 [2]. - Beikang Enterprise plans to reduce up to 1.392 million shares (0.33% of total shares) during the same period [2]. - Lei Xiaoyan plans to reduce up to 4.176 million shares (1% of total shares) from November 18, 2025, to February 17, 2026 [2]. Shareholder Basic Information - The shareholdings of the three shareholders are as follows: - Ningkang Enterprise holds 23.49 million shares (5.63% of total shares) [3]. - Beikang Enterprise holds 7.83 million shares (1.88% of total shares) [3]. - Lei Xiaoyan holds 15.66 million shares (3.75% of total shares) [3]. Compliance and Commitment Fulfillment - The share reduction plan complies with previous commitments made by the shareholders, who had locked their shares for 36 months post-IPO, with an automatic extension if the stock price fell below the IPO price within six months [3][4]. - As of the announcement date, all three shareholders have adhered to their share lock-up and reduction intentions without any violations [4].

Group 1 - The core point of the article is that Hendi Pharmaceutical (301211) announced plans for significant share reductions by several shareholders [1] Group 2 - Shareholder Jingmen Ningkang Enterprise Management Center (Limited Partnership), holding 5.63% of shares, plans to reduce holdings by up to 4.176 million shares, representing 1% of the total share capital [1] - Shareholder Jingmen Beikang Enterprise Management Center (Limited Partnership), holding 1.88% of shares, plans to reduce holdings by up to 1.392 million shares, representing 0.33% of the total share capital [1] - Shareholder Lei Xiaoyan, holding 3.75% of shares, plans to reduce holdings by up to 4.176 million shares, also representing 1% of the total share capital [1]

Core Viewpoint - Hendi Pharmaceutical (301211.SZ) announced plans for significant share reductions by major shareholders, indicating potential changes in ownership structure and market sentiment [1] Shareholder Reduction Plans - Shareholder Jingmen Ningkang Enterprise Management Center (Limited Partnership) plans to reduce its holdings by up to 4.176 million shares, representing 1% of the company's total share capital, within three months after the announcement [1] - Shareholder Jingmen Beikang Enterprise Management Center (Limited Partnership) intends to reduce its holdings by up to 1.392 million shares, accounting for 0.33% of the company's total share capital, within the same timeframe [1] - Shareholder Lei Xiaoyan plans to reduce her holdings by up to 4.176 million shares, also representing 1% of the company's total share capital, within three months following the announcement [1]

股东雷小艳计划在本公告披露之日起三个交易日后的三个月内以大宗交易方式或集中竞价交易方式合计 减持本公司股份不超过417.6万股(占公司总股本比例1%)。 亨迪药业（301211）(301211.SZ)发布公告，股东荆门市宁康企业管理中心(有限合伙)(以下简称"宁康企 管")计划在本公告披露之日起十五个交易日后的三个月内以大宗交易方式或集中竞价交易方式合计减持 公司股份不超过417.6万股(占公司总股本比例1%)。 股东荆门市倍康企业管理中心(有限合伙)(以下简称"倍康企管")计划在本公告披露之日起十五个交易日 后的三个月内以大宗交易方式或集中竞价交易方式合计减持本公司股份不超过139.2万股(占公司总股本 比例0.33%)。 ...